Send us a text

The Modern Urologist Podcast has launched a new miniseries, Precision Oncology and Prostate Cancer: The New Standard of Care, hosted by Dr. Paul Sieber and Ashleigh Renitsky, Oncology PA. This series will focus on the evolving role of genetic testing in prostate cancer care and its impact on personalized patient treatment plans.

Episode #1 - Genetic testing basics
The first installment will provide an overview of genetic testing, highlighting the difference between germline and somatic testing, and their implications for personalized treatment. This episode emphasizes the importance of integrating streamlined testing protocols into clinical practice, understanding test results to tailor therapies for patients, and leveraging genetic counselors. 

Send us a text

In this conversation, Dr. Tim Richardson from Wichita Urology and Dr. Ben Lowentritt from Chesapeake Urology discuss the integration and utilization of Advanced Practice Providers (APPs) in urology practices, particularly within advanced prostate cancer (APC) clinics. Dr. Lowentritt explains the benefits of using APPs to address physician shortages, increase efficiency, and more. 

Send us a text

Dr. Tim Richardson from Wichita Urology and Dr. Jonathan Henderson from Arkansas Urology discuss the use and benefits of Prolaris testing in prostate cancer management. Dr. Henderson elaborates on how Prolaris aids in decision-making for his prostate cancer patients, highlighting its role in reducing overtreatment and undertreatment. 

Send us a text

Dr. Tim Richardson from Wichita Urology interviews Dr. Scott Sellinger, the current president - elect of the Large Urology Group Practice Association (LUGPA). They discuss LUGPA's history, current status, and future goals. Initially founded to support large independent urology practices, LUGPA now includes any independent urology practice. Dr. Sellinger also highlights the challenges facing independent urology practices. 

*Episode was filmed 11/23 

Send us a text

In this episode of The Modern Urologist, Dr. Mark Edney is joined by Dr. Paul Sieber, a urologist from Lancaster, Pennsylvania, to discuss the use of genetic testing in the diagnosis and treatment of prostate cancer. Dr. Sieber emphasizes the importance of hereditary cancer testing, as well as tissue-based biomarkers like Prolaris®, in determining the best treatment plans for this prostate cancer patients.

Send us a text

On this episode of TMU we're diving deep into the rapidly evolving landscape of prostate cancer diagnosis and treatment with special guest, Dr. Adam Cole, a board-certified pathologist. Dr. Cole will discuss the traditional Gleason grading system, the limitations of pathology, and how incorporating genetic markers can improve patient outcomes.  

Send us a text

In this episode of TMU we have the pleasure of being joined by two urology experts, Dr. Ravi Rajan, Urologist, and Dr. William Ding, Radiation Oncologist, as they discuss topics ranging from genetic testing in prostate cancer for personalized treatment plans to the importance of collaboration between urologists and radiation oncologists. Our guests highlight the significance of effective communication and seamless integration within the treatment team. They also  shed light on the consequences of lack of collaboration and how it can impacts patient care and satisfaction. Listen along as they share valuable insights and practical tips for improving communication and collaboration between these specialties.

Send us a text

Join our panel of experts, Dr. Neal Shore, Dr. Ben Lowentritt, Dr. Ted Schaefer, and Dr. Jonathan Tward, as they discuss the various components and utility of a full workup for localized prostate cancer. They explore the importance of germline testing and how it has significant implications for personalized treatment choices. They will also discuss and examine the use of traditional biomarkers like PSA, PSA density, kinetics, and the Gleason grade system, as well as newer advancements in molecular markers and the potential use of artificial intelligence. Tune in as our experts share their insights, experiences, and expectations for the future of prostate cancer care.

Send us a text

On this episode of TMU, Dr. Mark Edney welcomes Dr. Deepak Kapoor as they dive into the world of private equity and healthcare policy. They discuss the opportunities and challenges faced by private practices in the field of Urology, and explore the topic of private equity with Dr. Kapoor's experiences as the chairman of Solaris Health. Listeners will gain insight into the differences between private equity and venture capital. Dr. Kapoor and Dr. Edney stress the importance of everyone having a voice in this thought-provoking conversation that highlights the ultimate goal of providing great patient care. 

Send us a text

 On this episode of TMU, we sit down with Ray Wezik, the Director of Policy and Advocacy for the American Urological Association (AUA), as we dive into the world of patient advocacy and lobbying. Ray shares his perspective as someone who works with over 75 patient advocacy organizations to leverage their voices and become better advocates together. We discuss the importance of collaboration between patient advocacy and medical professionals for effective efforts, and Ray shares insights on how networking events are bringing patients and urologists to state capitals to advocate for solutions and funding for research programs. Ray also shares valuable insights on working with regulatory agencies like CMS, and the value of determining CPT codes.